Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

May 16, 2014

Primary Completion Date

January 15, 2017

Study Completion Date

October 23, 2017

Conditions
Coronary Artery DiseaseCAD
Interventions
DRUG

regadenoson

Lexiscan® is being used off-label. The FDA Issued IND # is 119898. For the cardiac MRI, Lexiscan® will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.

DRUG

Optimark®

For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.

DEVICE

Myocardial perfusion MRI

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Daniel S. Berman

OTHER

NCT01949844 - Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies | Biotech Hunter | Biotech Hunter